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a b s t r a c t
A limited number of randomized controlled trials (RCTs) including economic analysis have supported the
cost-effectiveness of nurse practitioners and clinical nurse specialists delivering care in a variety of
settings. Our objective was to examine the quality of economic evaluations in this body of literature
using the Quality of Health Economic Studies (QHES) tool, and highlight which questions of the quality
assessment tool are being addressed adequately or require further attention within this body of
literature. Of 43 RCTs included in our systematic review, the majority (77%) fell in the poor study
quality quartile with an average total QHES score of 39 (out of 100). Only three studies (7%) were
evaluated as high quality. Inter-rater agreement (prior to consensus process) was high (83% agreement).
Four criteria for the quality of economic evaluations were consistently addressed: speciﬁcation of clear,
measurable objectives; pre-speciﬁcation of subgroups for subgroup analyses; justiﬁed conclusions based
on study results; and disclosure of study funding source. A clear statement of the primary outcome
measures, incremental analysis, and assessment of uncertainty were often unclear or missing. Due to
poor methodological quality, we currently lack a solid evidence base to draw clear conclusions about the
cost-effectiveness of nurse practitioners and clinical nurse specialists. Higher quality economic evalua-
tions are required to inform these questions.
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Introduction
Two top priorities within the current health care environment
are the reduction of costs without deteriorating the quality of
health care, and the improvement of patient outcomes while
maintaining reasonable costs (Gerkens et al., 2008; Ofman et al.,
2003). As a result, to help formulate health policy decisions there
is a growing interest in economic evaluations comparing costs and
outcomes within a wide range of health care programs (Gerkens
et al., 2008; Spiegel et al., 2004). One of the decisions health policy
makers face is whether and how they should integrate nurse
practitioners and clinical nurse specialists in the health care
system and they often request evidence about the cost-
effectiveness of these roles.
Review of literature
Clinical nurse specialists and nurse practitioners are considered
advanced practice nurses (International Council of Nurses, 2009).
Clinical nurse specialists are registered nurses with a graduate degree
in nursing who have expertise in a clinical specialty and perform an
advanced nursing role that includes practice, consultation, collabora-
tion, education, research, and leadership (Affara, 2009). Nurse
practitioners are deﬁned as registered nurses who have additional
education, preferably at the graduate level with advanced compe-
tencies to autonomously diagnose, prescribe medications and treat-
ments, order and interpret diagnostic tests, and perform speciﬁc
clinical procedures, as authorized by legislation and their regulatory
scope of practice (International Council of Nurses, 2009).
Studies on the effectiveness of nurse practitioners consistently
demonstrate high quality care and patient satisfaction (Horrocks,
Anderson, & Salisbury, 2002; Newhouse et al., 2011), and studies
on the effectiveness of clinical nurse specialists have shown
reductions in hospital length of stay, readmissions, emergency
room visits and associated costs (Fulton & Baldwin, 2004;
Newhouse et al., 2011). However, questions often arise about the
cost-effectiveness of these roles. Few attempts have been made to
consolidate and evaluate the quality of this speciﬁc body of
evidence. If we assume that higher quality health economic
analyses lead to better health care decisions, then the methodo-
logical quality of health care studies is important (Au, Prahardhi, &
Shiell, 2008). To this end, it is essential for evaluators and users of
this evidence to have a way to assess the quality of these studies
(Ofman et al., 2003).
We selected the Quality of Health Economic Studies (QHES)
instrument to evaluate the quality of cost-effectiveness analyses of
randomized controlled trials (RCTs) of nurse practitioners and clinical
nurse specialists. We selected this tool because it addresses speciﬁ-
cally questions about study quality of health economic analyses and
was designed by health economics experts to assess three types of
health economic analysis: cost-minimization, cost-effectiveness, and
cost-utility (Chiou et al., 2003; Ofman et al., 2003).
The purpose of our study was threefold. First, to highlight
which questions of the QHES are being addressed within this body
of literature and which require further attention; second, to assess
inter-rater agreement using the QHES tool on nurse practitioner
and clinical nurse specialist health economic studies; and third, to
evaluate study quality in three areas of nurse practitioner and
clinical nurse specialist health care economics: in-patient, out-
patient and transition care.
Materials and methods
Study identiﬁcation
This paper is one of a series of papers reporting ﬁndings from
our systematic review entitled, A systematic review of the cost-
effectiveness of nurse practitioners and clinical nurse specialists:
1980 to July 2012 (Donald et al., 2015; Donald et al., 2014;
Kilpatrick et al., 2014). The methods for our systematic review
are described in detail elsewhere (Donald et al., 2014). Brieﬂy, we
searched electronic databases and relevant websites, hand-
searched key journals, reviewed reference lists of relevant papers,
and contacted authors to identify all relevant published and
unpublished RCTs of nurse practitioner or clinical nurse specialist
cost-effectiveness reported from 1980 to July 2012 with no
restrictions on jurisdiction or language. RCTs met inclusion criteria
if they evaluated nurse practitioners or clinical nurse specialists, if
the impact of the nurse practitioner or clinical nurse specialist
could be isolated (e.g., if part of a multi-component or multi-
disciplinary intervention), and if the study included any objective
measures of health system utilization. These included length of
stay, re-hospitalization, costs of health care (e.g., hospital, profes-
sional, family costs) and health resource use (e.g., diagnostic tests,
prescriptions).
Relevant studies were categorized into six groups in which the
nurse practitioner or clinical nurse specialist was working in an
inpatient setting, outpatient setting (including primary care and
long-term care) or in a transition role. Transitional care referred to
the role of a nurse practitioner or clinical nurse specialist in
providing a range of health services designed to promote the safe
and timely transfer of patients between one level of care to
another or between health care settings (Naylor, Aiken,
Kurtzman, Olds, & Hirschman, 2011).
Study assessment using QHES
The QHES has been validated and shown to be simple and reliable
(Ofman et al., 2003). This tool includes 16 questions answered as
“yes” or “no” and each question has an assigned value ranging from
1 to 9 (Ofman et al., 2003). It assesses several economic study criteria
including whether the stated objectives, analytical perspective and
time horizon, outcome measures, data abstraction methods, and
analysis (incremental analysis and handling of uncertainty) are
clearly stated; the appropriateness of selected economic models
and associated cost measurements; and whether a clearly deﬁned
process to reduce the risk of bias was included (Table 1). Questions
answered “yes” receive the full point value and those answered “no”
receive no points. The sum of these points generates a summary
score on a scale of 0―100, with 0 indicating extremely poor quality
and 100 indicating high quality.
Two research assistants (SL [BSc with a background in actuarial
science and statistics] and KR [MSc with a background in the
conduct of systematic reviews]), trained by a health economist
investigator (DM), independently assessed the quality of each
study with respect to health economic analyses using the QHES
tool. Prior to implementing the QHES tool, the criteria for each
question were reviewed by the two assistants together with the
health economist investigator to determine whether more speciﬁc
guidance was necessary to ensure consistent interpretation for
each question. These elaborated descriptors are noted in Table 1 in
italics. The QHES tool was also pilot-tested on four studies by the
two research assistants prior to completing the evaluations.
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Discrepancies between research assistants were resolved by
discussion and if necessary, consultation with the health econo-
mist investigator. In some instances, a registered nurse investiga-
tor was consulted about expected time horizons for different
patient outcomes based on speciﬁc health conditions and inter-
ventions. Percent agreement between the two evaluators was
determined for each of the 16 QHES questions by calculating the
percentage of observed agreements for each question addressed or
not addressed (categorized as “yes” for question that was
addressed vs. “no” for not addressed).
We calculated the average total QHES score, with a standard
deviation, minimum and maximum value for all studies, and also
classiﬁed by the 6 groups representing combinations of nurse
practitioners and clinical nurse specialists in different roles.
Studies were classiﬁed according to quartiles for extremely poor
quality (0―24), poor quality (25–49), fair quality (50–74), and high
quality (75–100) as outlined by Spiegel et al. (2004).
Results
The search yielded 43 relevant RCTs. All were English language
published papers. The number of RCTs in each of the six categories
was as follows: clinical nurse specialist delivering in-patient care
N¼1; clinical nurse specialist delivering out-patient care N¼11;
clinical nurse specialist delivering transition care N¼13; nurse
practitioner delivering in-patient care N¼2; nurse practitioner
delivering out-patient care N¼11; and nurse practitioner deliver-
ing transition care N¼5.
Table 1
The 16 questions that comprise the Quality of Health Economic Studies Tool.
QUESTIONS POINTS
1. Was the study objective presented in a clear, speciﬁc, and measurable manner? 7
A study has to report that they explicitly measured costs and/or resource use in the abstract or introduction section of the report.
2. Were the perspective of the analysis (societal, third-party payer, etc.) and reasons for its selection stated? 4
All of the following criteria must apply:
a. Authors must explicitly state the perspective of the analysis;
b. Authors must state the reasons why they chose the perspective; and
c. Authors must have measured outcomes that were relevant to the stated perspective e.g. productivity (loss of work) for societal perspective.
3. Were variable estimates used in the analysis from the best available source (i.e., randomized controlled trial – best source, expert opinion – worst source)? 8
As all studies included in the review were RCTs, all studies received 8 points.
4. If estimates came from a subgroup analysis, were the groups pre-speciﬁed at the beginning of the study? 1
A point was lost only if a subgroup analysis was completed and subgroups were not pre-speciﬁed in either the protocol or methods section (i.e. if there was no
subgroup analysis, a point was assigned as default).
5. Was uncertainty handled by (1) statistical analysis to address random events, (2) sensitivity analysis to cover a range of assumptions? 9
For economic analyses only: Authors applied some kind of statistical analysis to examine joint uncertainty by reporting (1) Conﬁdence intervals around the ICER or a
cost-effectiveness acceptability curve (using bootstrapping), or (2) sensitivity analyses around the ICER, where the authors examine how a change made to input
values (costs and/or effects and/or resource use) changes the ICER.
6. Was incremental analysis performed between alternatives for resources and costs? 6
For economic analyses only: ICER (or the change in cost and change in effectiveness) had to be clearly reported. Studies must show the difference in costs and the
difference in effectiveness.
7. Was the methodology for data abstraction (including the value of health states and other beneﬁts) stated? 5
Only awarded if there was explicit methodological detail on costing/resource use and health/patient measures, above and beyond the source of costs and the name of
the scale used to measure health states or other effectiveness outcomes.
8. Did the analytic horizon allow time for all relevant and important outcomes? Were beneﬁts and costs that went beyond 1 year discounted (3–5%) and
justiﬁcation given for the discount rate?
7
This category is study/disease/outcome dependent – need to assess whether the follow-up time was long enough to capture any differences between groups (e.g. travel
costs more expensive early after discharge; resource use also likely to change over time), or appropriate for the measured outcome (e.g. if analyzing chronic disease, a
longer term of 10-20 years would be necessary; if the outcome is survival, lifetime costs would be appropriate)
Flag studies where it is unclear what the appropriate time horizon should be. Clinical investigator will then assist with the assessment.
9. Was the measurement of costs appropriate and the methodology for the estimation of quantities and unit costs clearly described? 8
Measurement (e.g. costs vs. charges; median reported instead of mean because of skewed data) must be appropriate and source of costing must be provided with
speciﬁc unit costs that either are reported or are calculable.
10. Were the primary outcome measure(s) for the economic evaluation clearly stated and were the major short-term, long- term, and negative outcomes
included?
6
An incremental cost-effectiveness measure had to be a primary outcome and the primary outcomes had to reﬂect the objective of the study. Similar to category 8, the
inclusion of major outcomes will be dependent on the study/disease. For example, an economic evaluation examining clinical nurse specialist intervention in patients
with diabetes should consider long-term and negative outcomes associated with the chronic condition (e.g. HbA1c levels at one year) whereas long-term outcomes
in an economic evaluation of an acute care nurse practitioner intervention may be less critical.
11. Were the health outcomes measures/scales valid and reliable? 7
If previously tested valid and reliable measures were not available, was justiﬁcation given for the measures/scales used? Authors needed to report validity of the health
outcome measure of effectiveness or reference a previous study where validity was conﬁrmed in a similar population. For example, was an appropriate measure for
utility used to calculate a quality adjusted life year?
12. Were the economic model (including structure), study methods and analysis, and the components of the numerator and denominator displayed in a clear,
transparent manner?
8
For economic analyses: authors must reference a model or a previous method used in a similar study.
13. Were the choice of economic model, main assumptions, and limitations of the study stated and justiﬁed? 7
For economic analyses: the assumptions and limitations of the model must have been discussed.
14. Did the author(s) explicitly discuss direction and magnitude of potential biases? 6
Usually in the discussion section – authors must discuss limitations and biases and must explicitly state how the bias would have affected results, and by how much.
15. Were the conclusions/recommendations of the study justiﬁed and based on the study results? 8
Usually in the discussion section – data should support the authors’ conclusions and recommendations.
16. Was there a statement disclosing the source of funding for the study? 3
TOTAL MAXIMUM SCORE 100
ICER¼ incremental cost-effectiveness ratio, RCT¼randomized controlled trial.
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Frequency of QHES questions addressed
For all studies combined, the questions of the QHES tool that
were most frequently addressed in the studies related to the
speciﬁcation of clear, measurable objectives (Q1); pre-speciﬁcation
of subgroups for subgroup analyses (Q4); justiﬁed conclusions
based on study results (Q15); and disclosure of the study funding
source (Q16) (Q3 was not considered here because it automatically
received the maximum eight points as all studies were RCTs)
(Fig. 1). By comparison, the areas of the QHES that were not well
addressed related to the study methodology such as the handling of
uncertainty (Q5), whether the duration of the study allowed for all
important or relevant outcomes to be captured (Q8), discussion of
potential biases (Q14), as well as other methodological items such
as the inclusion of appropriate reliable and valid outcomes (Q10,
Q11), data abstraction methods (Q7) and appropriate economic
modeling (Q2, Q6, Q12, Q13).
Even when analyzed by study group, the same four questions
related to stating objectives (Q1), pre-specifying subgroups (Q4),
justifying conclusions (Q15) and disclosing the study funding
source were answered most frequently (Q16) (Table 2). The
remaining questions (Q2, Q5–Q14) which were not often
addressed mostly related to the quality of the study design.
Inter-rater agreement
Average inter-rater percent agreement across the 15 questions
of the QHES (before the consensus process) was high at 83% (SE
4%). Percent agreement ranged from the lowest value of 36% (Q8),
related to the selection of an appropriate time horizon, to a high of
100% (Q6), asking whether an incremental analysis was performed
between alternatives for resources and costs (Table 3).
The two raters showed strong agreement for 9 questions, (Q1, Q2,
Q4, Q5, Q6, Q10, Q12, Q13 and Q16) in their ratings (more than 80%)
(Table 3). For the remaining 6 questions – related to the description of
the methodology (data abstraction, appropriate time horizon, costing
methodology), validity of the methods (valid measures and effect of
biases) and justiﬁcation of the conclusions – inter-rater agreement was
poor to moderate.
Results of quality QHES scoring among 43 RCTs
For all studies combined, the average total QHES score demon-
strated poor study quality at 39 (standard deviation¼15; mini-
mum¼19 and maximum¼83) points according to the QHES
quartiles (Spiegel et al., 2004) (Table 4). The majority of these studies
(77%) fell in the poor study quality quartile. Of note, the quality of
studies since 2000 was on average 13 points higher (mean 43717
points) versus those published before 2000 (mean 3077 points),
reﬂecting a trend towards improvement in the overall quality of these
studies.
When analyzed by groups, study quality was primarily in the
poor and fair quartiles (Table 5). None of the study groups
achieved an average score of 75 points or higher which is
considered to be high study quality (Spiegel et al., 2004). The
average total QHES scores by study groups ranged from 19 to 47
with the highest averages noted in the nurse practitioner and

















































Fig. 1. Percentage of nurse practitioner and clinical nurse specialist studies
addressing each question of the QHES (N¼43). QHES¼Quality of Health Economic
Studies. *Q3 automatically received full score for each study as all were randomized
controlled trials.
Table 2
Percentage of studies that addressed each question of the Quality of Health Economic Studies Tool by groups (N¼43).
QHES question CNS inpatient, N¼1 CNS outpatient, N¼11 CNS transition, N¼13 NP inpatient, N¼2 NP outpatient, N¼11 NP transition, N¼5
1 100 91 100 100 82 100
2 0 0 8 0 18 0
3a 100 100 100 100 100 100
4 100 82 54 100 82 80
5 0 9 0 0 18 0
6 0 18 0 0 27 0
7 0 82 38 0 64 0
8 0 55 38 0 64 20
9 0 27 8 0 27 0
10 0 9 0 0 18 0
11 0 82 46 0 55 40
12 0 18 0 0 18 0
13 0 9 8 0 0 0
14 0 27 8 50 18 0
15 0 82 69 100 100 40
16 100 73 100 100 100 100
CNS¼clinical nurse specialist, NP¼nurse practitioner, QHES¼Quality of Health Economic Studies.
a Q3 automatically received full score for each study as all were RCTs.
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Discussion
We assessed study quality using the QHES tool for 43 RCTs of
nurse practitioners and clinical nurse specialists in multiple
contexts that included health system outcomes. The majority of
these studies (77%) fell in the poor study quality quartile as
deﬁned by Spiegel et al. (2004) with an average total QHES score
of 39715, although there was a trend towards improvement in
the overall quality of these studies over time. Even when average
QHES scores were analyzed by the six nurse practitioners and
clinical nurse specialist groupings, the quality rating remained fair
to poor for all groups. The questions most frequently addressed in
the studies focused on the inclusion of clear objectives, pre-
speciﬁcation of subgroups, justiﬁcation of study conclusions and
the disclosure of funding for the study. By comparison, the areas of
the QHES that were not well addressed related to the study
methodology such as the handling of uncertainty, whether the
duration of the study allowed for all important or relevant out-
comes to be captured, discussion of potential biases, as well as
other methodological items such as the inclusion of appropriate
valid and reliable outcomes, data abstraction methods and appro-
priate economic modeling.
Our ﬁndings show only 3 of 43 studies met the criteria for high
quality (75–100) as measured by the QHES (Chiou et al., 2003).
Two were cost-effectiveness analyses of nurse practitioners in an
outpatient setting - one examined the effect on lowering blood
lipids in patients with coronary heart disease based on an RCT
(Paez & Allen, 2006) and one examined quality of life improve-
ments in children with eczema (Schuttelaar, Vermeulen, &
Coenraads, 2011). Paez and Allen (2006) conducted a cost-
effectiveness analysis in which costs (nurse practitioner time,
lipid-lowering drugs, lab monitoring) were linked to outcome
(low-density lipoprotein cholesterol) and found the annual incre-
mental cost-effectiveness ratio (ICER) of nurse practitioner case
management was $26/mg/dL reduction in low-density lipoprotein
cholesterol and $39 per percent reduction in low-density lipopro-
tein cholesterol. Schuttelaar et al. (2011) estimated savings of €925
per one point less improvement in infant quality of life, savings of
€751 per one point less in child quality of life, and €251 savings per
Table 3




1 Clear objective 89%
2 Perspective stated 91%
3 Best data source Not assessed as all the studies received the maximum 8 points for Q3 because our inclusion criteria
excluded non-RCT designs.
4 Subgroups pre-speciﬁed 89%
5 Uncertainty considered 98%
6 Incremental cost-effectiveness ratios
reported
100%
7 Data abstraction methodology 61%
8 Appropriate time horizon 36%
9 Costing methodology 73%
10 Primary outcomes 96%
11 Valid measures 77%
12 Model description 93%
13 Model appropriateness 98%
14 Effect of biases 75%
15 Conclusions justiﬁed 77%
16 Funding reported 93%
Average inter-rater agreement across 15
questions
83%
QHES¼Quality of Health Economic Studies; RCT¼randomized controlled trial.
Table 4
Breakdown by QHES quartile for all studies combined (N¼43).
Score range Quality quartile Number of studies Percentage of studies
0–24 Extremely poor 4 9
25–49 Poor 33 77
50–74 Fair 3 7
75–100 High 3 7
QHES¼Quality of Health Economic Studies.
Table 5














25–49 Poor 0 0
50–74 Fair 0 0






25–49 Poor 8 73
50–74 Fair 1 9






25–49 Poor 12 92
50–74 Fair 0 0






25–49 Poor 2 100
50–74 Fair 0 0






25–49 Poor 7 64
50–74 Fair 2 18






25–49 Poor 4 80
50–74 Fair 0 0
75–100 High 0 0
CNS¼clinical nurse specialist, NP¼nurse practitioner, QHES¼Quality of Health
Economic Studies.
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one point more satisfaction in the nurse practitioner group
compared with the dermatologist group at 12 months. The third
was a cost-effectiveness of clinical nurse specialists in an out-
patient setting in patients with rheumatoid arthritis (Tijhuis,
Zwinderman, Hazes, Breedveld, & Vliet Vlieland, 2003, 2002; van
den Hout, Tijhuis, Hazes, Breedveld, & Vliet Vlieland, 2003). van
den Hout et al. (2003) concluded that clinical nurse specialist care
was cost-saving – with an equivalent quality of life and utility at
lower societal cost by at least €5400.
All of these three high quality studies clearly deﬁned the study
objective and the approach and methods describing the economic
evaluation approach, including both the measures of effects and
costs. Of critical importance in the context of economic evaluation
methods, all of these studies combined costs and outcomes of the
intervention relative to the comparator and estimated an incre-
mental cost-effectiveness ratio. Further, these studies discussed
explicitly the direction and magnitude of potential biases and
justiﬁed their conclusions.
In our study, percent agreement between the two raters (before
the consensus process) was high at 83%, based on dichotomous
scoring, where “yes” indicated the question was addressed and
“no” indicated it was not addressed.
Other health economic evaluation studies, for example, in
digestive diseases (Spiegel et al., 2004) and physical therapy
(Peterson, Goodman, Karnes, Chen, & Schwartz, 2009) and surgical
treatment for obesity (Gerkens et al., 2008) also used the QHES
tool to evaluate the quality of economic evaluation studies. It is
difﬁcult to make a direct comparison of rater agreement because
methods varied. For example, Spiegel et al. (2004) reported a
kappa of 0.80 with a 10% random sampling of economic analyses
in digestive diseases, which does not reﬂect a total inter-rater
agreement across all the studies.
In obesity, Gerkens et al. (2008) found that inter-rater agreement
for most items was less than 0.40, but they did not provide a single
overall average over the 16 questions of the QHES for comparison. They
proposed several reasons for this poor agreement. First, the time
available to analyze studies varied between the two raters and the
methods of evaluation varied. One of the raters chose to refer to other
sources when there was insufﬁcient information, whereas the other
rater based their analysis on the main article only. Second, the
subjectivity of the experts may have inﬂuenced the response. For
example, severe raters may have been more likely to grade a 0 value
when a criterion was incomplete, while the other rater may have
tended to state full points if a study addressed a criterion even if not
completely. A third explanation for poor agreement with the QHES
may relate to the experience of the rater in economic evaluation, and
fourth, the questions could be interpreted in various ways. Based on
our experiences with this tool, we would also add that the experience
of the raters needs to be sufﬁciently broad to include the range of
health care disciplines assessed by the QHES tool. Ideally, to skillfully
use this tool, the evaluators would be at an advantage if they have
knowledge in three areas: clinical expertise about health conditions,
expected health care outcomes, and economic evaluation. This broad
scope of expertise may be difﬁcult to achieve and may explain the
varied range of percentage agreement over the 15 questions between
the two raters in our study, despite the overall high percent agreement.
Finally, Peterson et al. (2009) based their ﬁnal QHES scores on
consensus and consulting a third rater in instances of inter-rater
disagreement. Based on our experience with the QHES, we also
recommend that two people complete all the ratings indepen-
dently for all studies and that raters should undergo a consensus
process in order to reach a ﬁnal score when there are differences
in ratings (Gerkens et al., 2008; Peterson et al., 2009).
Since we further delineated the criteria for each question in the
QHES to improve rater agreement, there were instances where a
study did not receive points, but it may have by other raters. For
example, for Q5 regarding uncertainty, we further speciﬁed that
the authors needed to assess joint uncertainty of cost and effects.
Similarly, for Q11, we speciﬁcally required that the validity of
outcome measures was reported or justiﬁcation was given for the
measure with supporting references. Finally, none of these studies
received the seven points allocated by QHES scoring for stating the
assumptions and the limitations of the economic model. A limita-
tion of our study was related to the limited expertise of our raters
regarding some health conditions. In particular, the lower inter-
rater agreement for Q8 may be associated with limited back-
ground knowledge of health conditions by the two research
assistants. Closer involvement of a clinician would have helped
in arriving at consensus on the rating for this question.
The point of our evaluation was not to achieve perfect accuracy
in QHES scoring, but to assess consistently the quality of these
studies across the range of QHES scores and determine the
distribution across the QHES quality quartiles. It could be argued
that our evaluation criteria were too strict, but we attempted to
apply these consistently across the studies to enable comparisons.
Further, although QHES is a validated instrument, it was designed
to assess economic evaluation studies including cost-minimiza-
tion, cost-effectiveness and cost-utility analyses. Close to half of
the 43 studies we assessed included measures of health care
resource utilization only with no costing, and were therefore not
full economic evaluation studies.
Recommendations for future research
With these qualiﬁers, the majority of studies (93%) were scored
less than high quality. These ﬁndings are concerning and reﬂect
the need for future economic evaluations of nurse practitioners
and clinical nurse specialists that better address the criteria out-
lined in the QHES. Our ﬁndings highlight the importance of clear
criteria for interpreting and applying each of the 16 questions in
the QHES. We developed our own speciﬁc criteria to assist
independent raters in evaluating each question in a similar
manner. We recommend that raters should undergo a consensus
process in order to reach a ﬁnal score when there are differences
in ratings (Gerkens et al., 2008; Peterson et al., 2009)
Using the QHES, we were able to identify the key health
economic-related criteria that need to be better addressed in
future research regarding the cost-effectiveness of nurse practi-
tioners and clinical nurse specialists. Our ﬁndings suggest that
more attention is needed in the economic evaluation methods that
include both costs and outcomes combined to estimate
Fig. 2. Average total QHES scores by groups (N¼43). QHES¼Quality of Health
Economic Studies.
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incremental cost-effectiveness using clearly described and vali-
dated instruments and assessment of uncertainty.
Based on our experiences with the QHES tool we make four key
recommendations. First, we need to develop improved descriptions
of the speciﬁc criteria/guidelines for each of the QHES questions in
order for raters to evaluate study quality in a similar manner. Second,
expert consultants need to be made available to the raters as a very
broad scope of background knowledge is needed for the health
conditions assessed, outcome measurements and economic analyses.
Thirdly, all studies should be evaluated by two independent raters
when scoring studies with QHES because of the complexity of the
questions. And ﬁnally, a consensus process needs to be in place when
there are differences in ratings.
Conclusion
Before we can draw conclusions or make recommendations
regarding the cost-effectiveness of nurse practitioners and clinical
nurse specialists, we need to better understand the quality of the
existing research. Despite ﬁnding 43 RCTs of these advanced
practice nurses, almost half of these studies were not designed
to provide a comprehensive economic evaluation. Thus, we still
lack the required evidence to draw clear conclusions about APN
cost-effectiveness. Using the QHES tool, we found that only three
studies met the criteria for high quality economic evaluations. In
order to answer the question of cost-effectiveness of these APNs,
higher quality economic evaluations must be conducted that
include the relevant components. There is a clear need for more
research that incorporates standardized outcome measures, such
as the use of quality adjusted life years, and details both health
care costs and resource utilization. Only through comprehensive
high quality research that details the methods used, can we gain a
better understanding of the effectiveness and cost-effectiveness of
nurse practitioners and clinical nurse specialists.
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